The top 20 global innovative biopharma companies had a favorable year in 2021, reporting a 24.9% growth in aggregate market capitalization (MCAP), according to GlobalData.
This figure rose from $2.8 trillion on December 31, 2020 to $3.4 trillion as of December 31, 2021, the data provider’s research found.
A positive year-on-year (YoY) MCAP growth was reported for 14 of the top players, with five companies—BioNTech (Nasdaq: BNTX) (218.5%), Moderna (Nasdaq: MRNA) (149.1%), Novo Nordisk (NOVN: VX) (71.8%), Eli Lilly (NYSE: LLY) (63.6%) and Pfizer (NYSE: PFE) (61.9%) - demonstrating more than 50% growth in their MCAP in 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze